In addition, ALEXANDRA et al. showed that the balance of CD4+ and CD8+ lymphocytes infiltrating the tumor mesenchyme is a crucial factor in determining antitumor immune surveillance and has a solid prognostic value as a predictive marker for immunotherapy in treatable NSCLC. Here, CD8A is linked to non-small cell lung carcinoma.